209 related articles for article (PubMed ID: 34980598)
1. Sapanisertib plus Fulvestrant in Postmenopausal Women with Estrogen Receptor-Positive/HER2-Negative Advanced Breast Cancer after Progression on Aromatase Inhibitor.
García-Sáenz JÁ; Martínez-Jáñez N; Cubedo R; Jerez Y; Lahuerta A; González-Santiago S; Ferrer N; Ramos M; Alonso-Romero JL; Antón A; Carrasco E; Chen J; Neuwirth R; Galinsky K; Vincent S; Leonard EJ; Slamon D
Clin Cancer Res; 2022 Mar; 28(6):1107-1116. PubMed ID: 34980598
[TBL] [Abstract][Full Text] [Related]
2. Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION): overall survival, updated progression-free survival, and expanded biomarker analysis from a randomised, phase 2 trial.
Howell SJ; Casbard A; Carucci M; Ingarfield K; Butler R; Morgan S; Meissner M; Bale C; Bezecny P; Moon S; Twelves C; Venkitaraman R; Waters S; de Bruin EC; Schiavon G; Foxley A; Jones RH
Lancet Oncol; 2022 Jul; 23(7):851-864. PubMed ID: 35671774
[TBL] [Abstract][Full Text] [Related]
3. Sapanisertib Plus Exemestane or Fulvestrant in Women with Hormone Receptor-Positive/HER2-Negative Advanced or Metastatic Breast Cancer.
Lim B; Potter DA; Salkeni MA; Silverman P; Haddad TC; Forget F; Awada A; Canon JL; Danso M; Lortholary A; Bourgeois H; Tan-Chiu E; Vincent S; Bahamon B; Galinsky KJ; Patel C; Neuwirth R; Leonard EJ; Diamond JR
Clin Cancer Res; 2021 Jun; 27(12):3329-3338. PubMed ID: 33820779
[TBL] [Abstract][Full Text] [Related]
4. CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis.
Gao JJ; Cheng J; Bloomquist E; Sanchez J; Wedam SB; Singh H; Amiri-Kordestani L; Ibrahim A; Sridhara R; Goldberg KB; Theoret MR; Kluetz PG; Blumenthal GM; Pazdur R; Beaver JA; Prowell TM
Lancet Oncol; 2020 Feb; 21(2):250-260. PubMed ID: 31859246
[TBL] [Abstract][Full Text] [Related]
5. Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Baselga J; Im SA; Iwata H; Cortés J; De Laurentiis M; Jiang Z; Arteaga CL; Jonat W; Clemons M; Ito Y; Awada A; Chia S; Jagiełło-Gruszfeld A; Pistilli B; Tseng LM; Hurvitz S; Masuda N; Takahashi M; Vuylsteke P; Hachemi S; Dharan B; Di Tomaso E; Urban P; Massacesi C; Campone M
Lancet Oncol; 2017 Jul; 18(7):904-916. PubMed ID: 28576675
[TBL] [Abstract][Full Text] [Related]
6. Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer: Updated Results of ALTERNATIVE.
Johnston SRD; Hegg R; Im SA; Park IH; Burdaeva O; Kurteva G; Press MF; Tjulandin S; Iwata H; Simon SD; Kenny S; Sarp S; Izquierdo MA; Williams LS; Gradishar WJ
J Clin Oncol; 2021 Jan; 39(1):79-89. PubMed ID: 32822287
[TBL] [Abstract][Full Text] [Related]
7. Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR
Musolino A; Campone M; Neven P; Denduluri N; Barrios CH; Cortes J; Blackwell K; Soliman H; Kahan Z; Bonnefoi H; Squires M; Zhang Y; Deudon S; Shi MM; André F
Breast Cancer Res; 2017 Feb; 19(1):18. PubMed ID: 28183331
[TBL] [Abstract][Full Text] [Related]
8. Lasofoxifene versus fulvestrant for ER+/HER2- metastatic breast cancer with an ESR1 mutation: results from the randomized, phase II ELAINE 1 trial.
Goetz MP; Bagegni NA; Batist G; Brufsky A; Cristofanilli MA; Damodaran S; Daniel BR; Fleming GF; Gradishar WJ; Graff SL; Grosse Perdekamp MT; Hamilton E; Lavasani S; Moreno-Aspitia A; O'Connor T; Pluard TJ; Rugo HS; Sammons SL; Schwartzberg LS; Stover DG; Vidal GA; Wang G; Warner E; Yerushalmi R; Plourde PV; Portman DJ; Gal-Yam EN
Ann Oncol; 2023 Dec; 34(12):1141-1151. PubMed ID: 38072514
[TBL] [Abstract][Full Text] [Related]
9. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.
Finn RS; Crown JP; Lang I; Boer K; Bondarenko IM; Kulyk SO; Ettl J; Patel R; Pinter T; Schmidt M; Shparyk Y; Thummala AR; Voytko NL; Fowst C; Huang X; Kim ST; Randolph S; Slamon DJ
Lancet Oncol; 2015 Jan; 16(1):25-35. PubMed ID: 25524798
[TBL] [Abstract][Full Text] [Related]
10. Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study.
Rugo HS; Lerebours F; Ciruelos E; Drullinsky P; Ruiz-Borrego M; Neven P; Park YH; Prat A; Bachelot T; Juric D; Turner N; Sophos N; Zarate JP; Arce C; Shen YM; Turner S; Kanakamedala H; Hsu WC; Chia S
Lancet Oncol; 2021 Apr; 22(4):489-498. PubMed ID: 33794206
[TBL] [Abstract][Full Text] [Related]
11. Randomized Phase II Trial of Fulvestrant Plus Everolimus or Placebo in Postmenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy: Results of PrE0102.
Kornblum N; Zhao F; Manola J; Klein P; Ramaswamy B; Brufsky A; Stella PJ; Burnette B; Telli M; Makower DF; Cheema P; Truica CI; Wolff AC; Soori GS; Haley B; Wassenaar TR; Goldstein LJ; Miller KD; Sparano JA
J Clin Oncol; 2018 Jun; 36(16):1556-1563. PubMed ID: 29664714
[TBL] [Abstract][Full Text] [Related]
12. Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival.
Slamon DJ; Neven P; Chia S; Jerusalem G; De Laurentiis M; Im S; Petrakova K; Valeria Bianchi G; Martín M; Nusch A; Sonke GS; De la Cruz-Merino L; Beck JT; Ji Y; Wang C; Deore U; Chakravartty A; Zarate JP; Taran T; Fasching PA
Ann Oncol; 2021 Aug; 32(8):1015-1024. PubMed ID: 34102253
[TBL] [Abstract][Full Text] [Related]
13. Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer.
Turner NC; Oliveira M; Howell SJ; Dalenc F; Cortes J; Gomez Moreno HL; Hu X; Jhaveri K; Krivorotko P; Loibl S; Morales Murillo S; Okera M; Park YH; Sohn J; Toi M; Tokunaga E; Yousef S; Zhukova L; de Bruin EC; Grinsted L; Schiavon G; Foxley A; Rugo HS;
N Engl J Med; 2023 Jun; 388(22):2058-2070. PubMed ID: 37256976
[TBL] [Abstract][Full Text] [Related]
14. Design of SERENA-6, a phase III switching trial of camizestrant in
Turner N; Huang-Bartlett C; Kalinsky K; Cristofanilli M; Bianchini G; Chia S; Iwata H; Janni W; Ma CX; Mayer EL; Park YH; Fox S; Liu X; McClain S; Bidard FC
Future Oncol; 2023 Mar; 19(8):559-573. PubMed ID: 37070653
[TBL] [Abstract][Full Text] [Related]
15. Progression-free survival with endocrine-based therapies following progression on non-steroidal aromatase inhibitor among postmenopausal women with hormone receptor positive, human epidermal growth factor receptor-2 negative metastatic breast cancer: a network meta-analysis.
Ayyagari R; Tang D; Patterson-Lomba O; Zhou Z; Xie J; Chandiwana D; Dalal AA; Niravath PA
Curr Med Res Opin; 2018 Sep; 34(9):1645-1652. PubMed ID: 29781326
[TBL] [Abstract][Full Text] [Related]
16. Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial.
Tolaney SM; Wardley AM; Zambelli S; Hilton JF; Troso-Sandoval TA; Ricci F; Im SA; Kim SB; Johnston SR; Chan A; Goel S; Catron K; Chapman SC; Price GL; Yang Z; Gainford MC; André F
Lancet Oncol; 2020 Jun; 21(6):763-775. PubMed ID: 32353342
[TBL] [Abstract][Full Text] [Related]
17. Fulvestrant 500 mg Versus Exemestane in Postmenopausal Women With Metastatic Breast Cancer Resistant to Adjuvant Nonsteroidal Aromatase Inhibitors in Clinical Practice: A Multicenter Retrospective Study.
Xie Y; Li Y; Zhang Y; Zhang S; Li W; Guan X; Zhao Y; Gong C; Hu X; Zhang J; Cao E; Wang L; Ge R; Wang B
Clin Breast Cancer; 2019 Jun; 19(3):e452-e458. PubMed ID: 30846408
[TBL] [Abstract][Full Text] [Related]
18. Endocrine therapy with or without inhibition of epidermal growth factor receptor and human epidermal growth factor receptor 2: a randomized, double-blind, placebo-controlled phase III trial of fulvestrant with or without lapatinib for postmenopausal women with hormone receptor-positive advanced breast cancer-CALGB 40302 (Alliance).
Burstein HJ; Cirrincione CT; Barry WT; Chew HK; Tolaney SM; Lake DE; Ma C; Blackwell KL; Winer EP; Hudis CA
J Clin Oncol; 2014 Dec; 32(35):3959-66. PubMed ID: 25348000
[TBL] [Abstract][Full Text] [Related]
19. Fulvestrant plus palbociclib in advanced or metastatic hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer after fulvestrant monotherapy: Japan Breast Cancer Research Group-M07 (FUTURE trial).
Watanabe K; Niikura N; Kikawa Y; Oba M; Kobayashi K; Tada H; Ozaki S; Toh U; Yamamoto Y; Tsuneizumi M; Okuno T; Iwakuma N; Takeshita T; Iwamoto T; Ishiguro H; Masuda N; Saji S
Breast Cancer Res Treat; 2023 Jun; 199(2):253-263. PubMed ID: 37000345
[TBL] [Abstract][Full Text] [Related]
20. Overall Survival and Exploratory Biomarker Analyses of Abemaciclib plus Trastuzumab with or without Fulvestrant versus Trastuzumab plus Chemotherapy in HR+, HER2+ Metastatic Breast Cancer Patients.
Tolaney SM; Goel S; Nadal J; Denys H; Borrego MR; Litchfield LM; Liu J; Appiah AK; Chen Y; André F
Clin Cancer Res; 2024 Jan; 30(1):39-49. PubMed ID: 37906649
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
